# Impact of maternal aspirin therapy on the maternal/fetal unit at delivery: A study of aspirin pharmacokinetics, pharmacodynamics, and pharmacogenomics through pregnancy

> **NIH NIH R21** · THOMAS JEFFERSON UNIVERSITY · 2020 · $290,489

## Abstract

PROJECT SUMMARY
Background: While there has been much research on efficacy of aspirin for preeclampsia
prevention there is little information on the individual variability in response to aspirin
therapy, how this changes through gestation, and downstream neonatal impact of
maternal therapy.
OBJECTIVE: This proposal has two aims to study the individual predictors of response to aspirin
through the course of pregnancy and the impact of aspirin therapy on the maternal/neonatal unit.
Ultimately our results will explore a common genetic variant that may drive racial disparities in
outcomes and response to aspirin therapy, identify neonatal epigenetic changes related to aspirin
therapy and HDP that could elucidate long term impact of aspirin therapy on offspring, and further
characterize aspirin pharmacology in pregnancy to guide dosing.
Aim 1: Development of delivery sample cohort to evaluate the impact of aspirin on the
maternal/fetal unit at delivery, and how PAR4 genotype, HDP, and individual factors may modify
the observed effect
Aim 2: Longitudinal evaluation of pharmacokinetics and pharmacodynamics of aspirin in pregnant
patients at high risk for preeclampsia
Methods: This proposal has a two-pronged study design. Aim 1 will be conducted through
recruitment of patients admitted for delivery at Thomas Jefferson University Hospital. The
exposure of interest in this cohort will be aspirin, with a planned nested case/control study of
those with and without a diagnosis of hypertensive disorder of pregnancy (HDP). Aim 2 will be a
longitudinal addition to an existing R21cohort enrolled in the first trimester to include a third
trimester assessment of pharmacokinetics/pharmacodynamics (PK/PD) of aspirin and how
individual factors impact aspirin PK/PD in pregnancy.

## Key facts

- **NIH application ID:** 10177563
- **Project number:** 3R21HD101127-01S1
- **Recipient organization:** THOMAS JEFFERSON UNIVERSITY
- **Principal Investigator:** Rupsa Chaudhury Boelig
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $290,489
- **Award type:** 3
- **Project period:** 2020-04-01 → 2022-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10177563

## Citation

> US National Institutes of Health, RePORTER application 10177563, Impact of maternal aspirin therapy on the maternal/fetal unit at delivery: A study of aspirin pharmacokinetics, pharmacodynamics, and pharmacogenomics through pregnancy (3R21HD101127-01S1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10177563. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*